Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters

Sung Yoon Lim, MD, Sun Won Kim, MD, Eung Ju Kim, MD, Jun Hyuk Kang, MD, Su A Kim, MD, Yun Kyung Kim, MD, Jin Oh Na, MD, Cheol Ung Choi, MD, Hong Euy Lim, MD, Seong Woo Han, MD, Seung-Woon Rha, MD, Chang Gyu Park, MD, Hong Seog Seo, MD, and Dong Joo Oh, MD

Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

ABSTRACT

Background and Objectives: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have been conducted with different ARBs. We compared these effects in patients with uncomplicated hypertension who were receiving telmisartan or valsartan.

Subjects and Methods: The subjects were patients with essential hypertension (48.4 ± 9.6 years) who were randomly assigned to take either telmisartan (80 mg/day, n=30) or valsartan (160 mg/day, n=30) for 12 weeks. Their anthropometric, laboratory, vascular, and echocardiographic data were measured at baseline and at the end of the study.

Results: Baseline characteristics were not significantly different between the two groups, except for the carotid-femoral pulse wave velocity (cfPWV; telmisartan group vs. valsartan group; 841.2 ± 131.0 vs. 761.1 ± 104.4 cm/s, p<0.05). After 12 weeks, BP had fallen to a similar extent with mean reductions in the systolic and diastolic BP of 20.7 ± 18.1 and 16.3 ± 13.0 mm Hg (p<0.001, respectively) for the telmisartan and 22.5 ± 17.0 and 16.8 ± 9.3 mm Hg (p<0.001, respectively) for the valsartan group. Although the cfPWV and left ventricular mass index (LVMI) fell significantly only with the administration of telmisartan, they were not significantly different when baseline cfPWV was considered. The differences in the cfPWV and LVMI changes from baseline between the two groups were also not significant after adjusting for baseline cfPWV. No significant changes in other vascular, metabolic, or inflammatory parameters were observed with either treatment.

Conclusion: The effects of a 12-week treatment with the two ARBs, telmisartan and valsartan, on cardiovascular, metabolic, and inflammatory parameters were not different in patients with uncomplicated hypertension.

KEY WORDS: Hypertension; Valsartan.
Further, RAS blockers, including angiotensin-converting enzyme inhibitors (ACEIs) and ARBs, reduce the incidence of new-onset diabetes. Recent in vitro and animal studies have suggested that some ARBs act as partial peroxisome proliferator-activated receptor-gamma (PPARγ) agonists and that this does not depend on an AT-1 receptor blockade; thus, this may improve insulin sensitivity and the lipid profile.

Inflammation is one of the plausible mechanisms by which angiotensin II accelerates the development of atherosclerosis and evidence exists that inflammatory markers are reduced by ARBs independent of changes in BP.

The cardiovascular, metabolic, and anti-inflammatory effects of ARBs are thought to be similar and rarely compared within the drug class, though important structural differences exist among the various compounds. The purpose of this study was to compare these cardiovascular, metabolic, and anti-inflammatory effects between telmisartan and valsartan in uncomplicated hypertensive subjects.

Subject and Methods

Subjects

We performed a prospective, randomized, open-label, fixed-monotherapy, single center, parallel-group study. Patients were recruited from the Cardiovascular Center at Korea University Guro Hospital, Seoul, Korea. Inclusion criteria were newly diagnosed or known hypertensive subjects who were not taking antihypertensive agents for more than the last 4 weeks. Patients with the following conditions were excluded: 1) hyperkalemia >5.5 mmol/L, 2) serum creatinine >2 mg/dL, 3) hemoglobin A1c (HbA1c) >8.0%, 4) secondary hypertension, 5) hormone therapy or steroid administration, 6) taking antidiabetic or lipid-lowering agents, 7) known coronary artery disease or significant atherosclerotic disease of other vessels and, 8) clinically significant nervous, gastrointestinal, or respiratory disease, or malignant disease. All subjects gave their written informed consent, and the Korea University institutional review board approved the study protocol in accordance with the Declaration of Helsinki of the World Medical Association.

After a 2-week run-in period, patients were randomized to receive either telmisartan (80 mg/day; n=30) or valsartan (160 mg/day; n=30) for a 12-week open-labeled phase. Patients were requested to take their study medication with water in the morning and at approximately the same time each day. BPs were recorded twice every 2 minutes by a research nurse using a random zero mercury sphygmomanometer fitted with an appropriate cuff size. The recorded BPs were averaged for use in the analysis. Patients in which systolic pressure was >140 mm Hg or diastolic pressure was >90 mm Hg were defined as having hypertension.

Anthropometric and laboratory measurements

Age, gender, body weight, waist circumference, and body mass index (BMI) were recorded. Waist circumference was measured at the midpoint between the lower border of the rib edge and the iliac crest, and BMI was calculated as the weight/height² (kg/m²). Current smoking was defined as active smoking within the past 12 months. All blood samples were obtained in the morning with subjects in a fasting state. Insulin resistance was calculated by the Homeostasis Model of Assessment (HOMA).

Measurement of pulse wave velocity

All procedures were conducted in a controlled environment by an experienced technician who was blinded to the clinical information. The carotid-femoral pulse wave velocity (cfPWV) was determined using the PP-1000 semiautomatic device (Hanbyul Meditech, Seoul, Korea). Briefly, the left common carotid artery (CCA), radial artery, femoral artery, and dorsal artery pressure waveforms were recorded non-invasively using a tonometric pressure sensor. An electrocardiogram, phonocardiogram and four-channel pressure waveforms were simultaneously measured. The distance (D) traveled by the pulse wave was automatically obtained from the age- and height-based distance of the upper and lower extremity arteries of Koreans, and this was provided by the Korea Research Institute of Standards and Science. The pulse transit time (T), which was measured between the feet of the pressure waveforms that were recorded at two different recording points (the foot-to-foot method), was automatically determined. The PWV was automatically calculated as D/T. Among the carotid-femoral, carotid-radial, and femoral-dorsal PWVs, we only used the cfPWV in the current study because it is the most clinically relevant index. Pearson’s correlation coefficient for intraobserver reproducibility was 0.99 (p < 0.001). In the Bland-Altman plot of intraobserver measurement, the mean difference in the repeated measurements was -0.056±0.223, and most of the values ranged within a mean±1.96 SD.

Measurement of the carotid intima medial thickness

B-mode ultrasound measurements were performed with...
an 11-MHz linear-array transducer that was connected to a Vivid-7 echocardiograph (General Electronics Corp., Horten, Norway). The right and left CCA intima-media thickness (IMT) were measured at least 10 mm proximal to the bifurcation. Maximum and mean IMT values were automatically calculated using programmed software (MATH, METRIS Co., Argenteuil, France).

**Measurement of flow-mediated dilation**

We tested the function of vascular endothelial cells using flow-mediated dilation (FMD). FMD was assessed using brachial artery two-dimensional ultrasonography (Vivid-7, General Electronics Corp., Horten, Norway) using a modification of the method of Corretti et al. Measurements were performed on the left arm with subjects in the supine position after a 10-20 minute rest in a quiet dark room at a temperature of 22°C. The brachial artery was scanned longitudinally, just above the antecubital crease, using an 11-MHz probe. Hyperemia was induced by inflating a pneumatic cuff to 230 to 250 mm Hg for 5 minutes on the middle of the forearm; the maximum arterial diameter was then measured 45-60 seconds after sudden deflation of the cuff. The maximum diameter during hyperemia compared with the baseline diameter was used for analysis. We measured each diameter three times during two beats, and the mean data were used for the final analysis. Measurements were conducted by an independent observer who remained blinded to the medication of the study. FMD was defined as the percent increase in the arterial diameter during hyperemia, i.e., \(100 \times \frac{\text{diameter after hyperemia} - \text{baseline diameter}}{\text{baseline diameter}}\).

**Echocardiographic measurement**

Two-dimensional and guided M-mode echocardiograms were performed on each subject by a single sonographer and confirmed by an experienced cardiologist who were blinded to the clinical information. A commercially available machine (Vivid-7, General Electronics Corp., Horten, Norway) with a 1.5-4.0 MHz transducer was used. The left ventricular internal end-diastolic dimension, the end systolic dimension, and the septal and posterior wall thicknesses were measured on the leading edge to the leading edge, according to the guidelines of the American Society of Echocardiography. The left ventricular mass was calculated according to the formula of Devereux et al. The left ventricular mass index (LVMI) was calculated as the left ventricular mass/body surface area (g/m²).

**Statistical analysis**

Data were analyzed by nonparametric methods to avoid assumptions about the distribution of the measured variables. Comparisons between groups were made using the Mann-Whitney U-test. Differences between baseline and post-treatment values were analyzed using the Wilcoxon’s signed-rank test. The Mann-Whitney analysis was used for comparing changes and percent changes between the baseline and post-treatment values in patients receiving telmisartan versus those receiving valsartan. Differences in the changes in cfPWV and LVMI from baseline between the treatment groups were analyzed with an analysis of covariance, in which the possible confounding effects of baseline cfPWV, BP change, and heart rate change were considered as covariates by including them into the model. The distributions of continuous variables in the groups are expressed as means±SDs. A p<0.05 was considered statistically significant. All statistical results were based on two-sided tests. The data were analyzed using SPSS for Windows (Version 12.0; SPSS Inc., Chicago, IL, USA).

**Results**

**Subject characteristics**

A total of 120 patients were screened, of whom 65 were eligible to enter the study. These patients were randomized to the telmisartan (n=33) and valsartan (n=32) groups. Three patients in the telmisartan group (two consented withdrawal, one lost to follow-up) and two patients in the valsartan group (one consented withdrawal, one lost to follow-up) dropped out of the study before obtaining a postbaseline measurement. This remaining 60 patients (telmisartan group=30 and valsartan group=30) formed the intent to treat (ITT) population, defined as all randomized patients who provided baseline and follow-up data.

The study subjects consisted of 38 men (63.3%) and 22 women (36.7%), with a mean age of 48.4±9.6 years old. The baseline characteristics of the hypertensive patients are shown in Table 1. The clinical characteristics of the two groups were well matched except for the cfPWV, which was significantly greater in the telmisartan group than that in the valsartan group (841.2±131.0 cm/s vs. 761.1±104.4 cm/s, p<0.05).

**Blood pressure control**

After 12 weeks of treatment, both telmisartan and valsartan significantly reduced systolic (p<0.001) and diastolic BPs (p<0.001) compared with baseline (Table 2). The mean reductions in systolic BP were 20.7±18.1 mm Hg in the telmisartan group and 22.5±17.0 mm Hg in the valsartan group. The mean reductions in diastolic BP were 16.3±13.0 mm Hg in the telmisartan group and 16.8±9.3 mm Hg in the valsartan group. No significant changes in heart rate compared with baseline were observed in either treatment.

**Metabolic and inflammatory profile**

A 12-week administration of telmisartan and valsartan did not result in any changes in BMI, waist circumference, HbA1c, fasting plasma glucose, fasting plasma insulin, HOMA, or adiponectin compared with baseline (Table 2). No significant
changes were observed compared with baseline in the lipid profiles of the patients who had received telmisartan or valsartan, but there were trends for a reduction in total cholesterol (-4.7%, p=0.075) and triglyceride (-5.6%, p=0.058) in the telmisartan group (Table 2). Interleukin-6 was not significantly reduced in either group.

Cardiovascular indices

After 12-weeks of telmisartan treatment, a significant reduction in cfPWV was observed (-7.5%, p<0.05), whereas the decrease in the valsartan group was not statistically significant (Table 2). However, the results were the reverse when baseline cfPWV, which was significantly higher in the telmisartan group than in the valsartan group, was considered in the analysis fraction, LVMI: left ventricular mass index

Table 1. Demographics and baseline characteristics of the hypertensive patients randomized to treatments with 80 mg telmisartan and 160 mg valsartan for 12 weeks

| Characteristics | Telmisartan group (n=30) | Valsartan group (n=30) | p |
|-----------------|--------------------------|-----------------------|---|
| Age (years)     | 48.2 ± 10.0              | 49.4 ± 10.5           | 0.790 |
| DBP (mm Hg)     | 101.1 ± 11.4             | 99.3 ± 10.5           | 0.625 |
| HR (bpm)        | 72.2 ± 9.4               | 76.9 ± 9.7            | 0.056 |
| HbA1c (%)       | 5.8 ± 0.7                | 5.6 ± 0.4             | 0.445 |
| FPG (mg/dL)     | 100.6 ± 13.9             | 96.9 ± 12.1           | 0.185 |
| FPI (μIU/mL)    | 6.2 ± 5.9                | 6.1 ± 3.7             | 0.658 |
| HOMA            | 1.6 ± 1.6                | 1.5 ± 0.9             | 0.750 |
| TC (mg/dL)      | 193.2 ± 34.4             | 198.5 ± 31.8          | 0.636 |
| TG (mg/dL)      | 162.5 ± 76.5             | 165.2 ± 127.9         | 0.297 |
| HDL-C (mg/dL)   | 49.4 ± 12.4              | 52.0 ± 13.6           | 0.534 |
| LDL-C (mg/dL)   | 128.7 ± 29.0             | 130.5 ± 27.6          | 0.959 |
| Adiponectin (ng/mL) | 59.2 ± 38.9            | 76.4 ± 57.4           | 0.220 |
| IL-6 (pg/mL)    | 1.41 ± 1.80              | 1.35 ± 1.50           | 0.894 |
| cPWV (cm/s)     | 841.2 ± 131.0            | 761.1 ± 104.4         | 0.041 |
| Carotid IMT (mm) | 0.73 ± 0.17             | 0.67 ± 0.13           | 0.158 |
| FMD (%)         | 7.1 ± 4.1                | 8.4 ± 4.3             | 0.150 |
| LV EF (%)       | 62.0 ± 1.5               | 62.5 ± 1.3            | 0.179 |
| LVMI (g/m²)     | 126.3 ± 26.8             | 124.2 ± 24.3          | 0.767 |

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, HbA1c: glycosylated hemoglobin, FPG: fasting plasma glucose, FPI: fasting plasma insulin, HOMA: homeostasis assessment model of insulin resistance, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, IL-6: interleukin-6, cPWV: carotid-femoral pulse wave velocity, IMT: intima-media thickness, FMD: flow-mediated dilation, LV EF: left ventricular ejection fraction, LVMI: left ventricular mass index

Table 2. Effects of administering 80 mg telmisartan and 160 mg valsartan for 12 weeks in patients with hypertension

| Characteristics | Telmisartan group (n=30) | Valsartan group (n=30) | p |
|-----------------|--------------------------|-----------------------|---|
| SBP (mm Hg)     | Baseline 153.2 ± 18.9    | 151.7 ± 16.1          | 0.425 |
| Study end 133.3 ± 15.5 | 129.2 ± 15.1 | <0.001 | <0.001 |
| DBP (mm Hg)     | Baseline 101.1 ± 11.4    | 99.3 ± 10.5           | 0.329 |
| Study end 84.8 ± 9.8 | 82.4 ± 11.3  | <0.001 | <0.001 |
| BMI (kg/m²)     | Baseline 25.0 ± 2.7      | 25.0 ± 2.3            | 0.657 |
| Study end 25.0 ± 2.8 | 24.8 ± 2.1  | 0.932 | 0.131 |
| Waist (cm)      | Baseline 86.4 ± 8.3      | 86.2 ± 6.6            | 0.695 |
| Study end 86.0 ± 7.9 | 85.8 ± 6.3 | 0.201 | 0.097 |
| HbA1c (%)       | Baseline 5.8 ± 0.7       | 5.6 ± 0.4             | 0.285 |
| Study end 5.7 ± 0.6 | 5.5 ± 0.4  | 0.852 | 0.641 |
| FPG (mg/dL)     | Baseline 100.6 ± 13.9    | 96.9 ± 12.1           | 0.112 |
| Study end 100.4 ± 13.5 | 94.8 ± 9.7 | 0.983 | 0.578 |
| FPI (μIU/mL)    | Baseline 6.2 ± 5.9       | 6.1 ± 3.7             | 0.906 |
| Study end 8.0 ± 5.5 | 7.6 ± 4.4  | 0.098 | 0.139 |
| HOMA            | Baseline 1.6 ± 1.6       | 1.5 ± 0.9             | 0.679 |
| Study end 2.0 ± 1.4 | 1.8 ± 1.1  | 0.133 | 0.206 |
| TC (mg/dL)      | Baseline 193.2 ± 34.4    | 198.5 ± 31.8          | 0.060 |
| Study end 182.2 ± 33.1 | 198.5 ± 30.7 | 0.075 | 0.902 |
| HDL-C (mg/dL)   | Baseline 162.5 ± 76.5    | 165.2 ± 127.9         | 0.813 |
| Study end 140.3 ± 67.2 | 168.3 ± 148.6 | 0.058 | 0.544 |

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, HbA1c: glycosylated hemoglobin, FPG: fasting plasma glucose, FPI: fasting plasma insulin, HOMA: homeostasis assessment model of insulin resistance, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, IL-6: interleukin-6, cPWV: carotid-femoral pulse wave velocity, IMT: intima-media thickness, FMD: flow-mediated dilation, LV EF: left ventricular ejection fraction, LVMI: left ventricular mass index
The adjusted mean (95% confidence interval (CI)) change in cfPWV from baseline was -41.8 (-87.4, 3.7) cm/s in the telmisartan group and -18.7 (-38.3, 1.0) cm/s in the valsartan group (Fig. 1). The adjusted mean (95% CI) change in LVMI from baseline was -10.9 (-24.5, 2.6) g/m² in the telmisartan group and 7.7 (-5.8, 21.3) g/m² in the valsartan group (Fig. 2).

**Differences in the changes of the study variables from baseline to the end of the study**

When we compared changes between baseline and the post-treatment values in patients receiving telmisartan versus those receiving valsartan, no significant differences were observed for any of the anthropometric, hemodynamic, metabolic, or cardiovascular variables including the cfPWV (-80.5±189.2 cm/s vs. -39.1±138.6 cm/s, p=0.399), but a significant difference was observed for the LVMI. The mean changes in the LVMI were -9.6 ±45.3 g/m² in the valsartan group versus -22.7 g/m² in the telmisartan group (Fig. 2).

Table 2. Continued

| Characteristics | Telmisartan group | Valsartan group | p  |
|-----------------|-------------------|-----------------|----|
| LDL-C (mg/dL)   |                   |                 |    |
| Baseline        | 128.7±29.0        | 130.5±27.6      | 0.290 |
| Study end       | 135.5±29.2        | 131.1±22.4      | 0.375 |
| p               | 0.375             | 0.900           |    |
| Adiponectin (ng/mL) |             |                 |    |
| Baseline        | 59.2±38.9         | 76.4±57.4       | 0.182 |
| Study end       | 60.2±32.3         | 80.9±60.3       | 0.858 |
| p               | 0.858             | 0.541           |    |
| IL-6 (pg/mL)    |                   |                 |    |
| Baseline        | 1.41±1.80         | 1.35±1.50       | 0.249 |
| Study end       | 1.19±1.49         | 1.15±0.89       | 0.452 |
| p               | 0.452             | 0.620           |    |
| cPWV (cm/s)     |                   |                 |    |
| Baseline        | 841.2±131.0       | 761.1±104.4     | 0.252 |
| Study end       | 760.7±136.8       | 722.0±100.6     | 0.023 |
| p               | 0.023             | 0.128           |    |
| Carotid IMT (mm)|                   |                 |    |
| Baseline        | 0.73±0.17         | 0.67±0.13       | 0.217 |
| Study end       | 0.70±0.17         | 0.66±0.16       | 0.061 |
| p               | 0.061             | 0.213           |    |
| FMD (%)         |                   |                 |    |
| Baseline        | 7.1±4.1           | 8.4±4.3         | 0.088 |
| Study end       | 8.0±3.0           | 9.1±3.2         | 0.118 |
| p               | 0.118             | 0.213           |    |
| LVMl (g/m²)     |                   |                 |    |
| Baseline        | 126.3±26.8        | 124.2±24.3      | 0.193 |
| Study end       | 116.7±25.3        | 130.6±41.6      | 0.018 |
| p               | 0.018             | 0.781           |    |

SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, HbA1c: glycosylated hemoglobin, FPG: fasting plasma glucose, FPI: fasting plasma insulin, HOMA: homeostasis assessment model of insulin resistance, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, IL-6: interleukin-6, cPWV: carotid-femoral pulse wave velocity, IMT: intima-media thickness, FMD: flow-mediated dilation, LVMI: left ventricular mass index.
respectively, both of which were not significant after adjusting for baseline cfPWV (Figs. 1 and 2). When we further adjusted BP changes and heart rate changes in addition to baseline cfPWV, the mean (95% CI) difference in the cfPWV changes, 38.7 (-30.3, 107.7) cm/s, was also not significant (p = 0.265).

Discussion

We compared the cardiovascular, metabolic, and anti-inflammatory effects of two ARB drugs, telmisartan and valsartan, in a 12-week treatment trial in patients with uncomplicated hypertension. The systolic and diastolic BPs were significantly reduced but none of the other study variables changed significantly in either group, except for cfPWV in the valsartan group. None of the changes in the measured cardiovascular, metabolic and inflammatory parameters were significantly different between the two groups in the present study.

ARBs are preferred agents to prescribe for hypertension management in Korea as well as in other countries. ARBs are a valuable alternative to ACEIs in contrast to ACEIs, which many patients, particularly women, Asians, and blacks, are unable to tolerate due to adverse side-effects. ARBs are highly effective first-line agents for reducing BP as well as providing cardiovascular and renal protection, and they have the cardinal strength of improved, placebo-like tolerability and higher patient compliance rates compared with other drug classes.

Although ARBs share a common mechanism of action, their molecular structures and pharmacological profiles vary. However, there is a lack of large, independent, direct comparative trials for drugs within the ARB class.

Telmisartan is a compound that can simultaneously block RAS and activate PPARγ so it has the potential to treat both the hemodynamic and biochemical features of metabolic syndrome such as hypertension, insulin resistance, and dyslipidemia. Benson et al. recently reported that telmisartan could function as a partial PPARγ agonist, which could influence the expression of the PPARγ target genes involved in carbohydrate and lipid metabolism, whereas telmisartan reduces glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet. They also reported that none of the other commercially available ARBs appeared to activate PPARγ when tested at concentrations typically achieved in the plasma with conventional oral dosing.

The ability to activate PPARγ in addition to blocking the RAS led us expect that some beneficial effects on insulin resistance, lipid profiles, adiponectin, and IL-6 would be found in the telmisartan group. But, neither telmisartan nor valsartan showed improvement in these indices. It might be because these indices are not significantly abnormal to fulfill the metabolic syndrome criteria at baseline in our uncomplicated hypertensive subjects and the treatment duration was too short to demonstrate significant changes. Nevertheless, trends for a reduction in total cholesterol (-4.7%, p = 0.075) and triglyceride (-5.6%, p = 0.058) were observed in the telmisartan group.

Telmisartan is the longest acting ARB currently available, with a mean plasma half-life of approximately 24 hours, and it has a better BP trough-to-peak ratio in the range of 0.7-1.0 in addition to having the largest distribution volume (500 L), the strongest binding affinity, and the longest duration of receptor blockade compared with other agents in this class. Telmisartan also has a rapid onset of action (maximum plasma concentrations are achieved 0.5-1.5 hours after administration). Compared with losartan, telmisartan shows superior efficacy during the day-time, night-time, and last 6 hours of the dosing interval. Moreover, using ambulatory BP monitoring, 80 mg telmisartan is superior to 160 mg valsartan in the last 6 hours of the dosing interval. These features of telmisartan might have caused the significant reduction in the cfPWV from baseline, which represents aortic stiffness. But the reduction was marginally insignificant after adjusting for baseline cfPWV, which was significantly higher in the telmisartan group, suggesting that the baseline level of aortic stiffness may strongly affect the changes in cfPWV caused by antihypertensive treatment. In contrast, the adjusted cfPWV decreased significantly from baseline in the valsartan group. Although the mean reductions in BP were not significantly different between the two groups, slightly more of a reduction (1.7 and 0.6 mm Hg, systolic and diastolic, respectively) in the valsartan group may have affected the result. Because BP is one of the strongest influencing factors of aortic stiffness, a reduction in cfPWV along with decreasing BP even with a short-term follow-up, was not surprising. However, the difference in the changes of the adjusted cfPWV from baseline was not significant between the two treatments (Fig. 1).

Because the aorta is the first afterload interface for the left ventricle, LVMI should be significantly affected by aortic stiffness. Therefore, we also adjusted baseline cfPWV when we compared the changes in LVMI from baseline to the two groups. The adjusted changes in LVMI were not significant in either group, and the difference in the LVMI changes between the two groups was also not significant, though it was favorable for the telmisartan group (Fig. 2). A 12-week ARB treatment may be insufficient to show a significant improvement in LVMI either by lowering the BP or by BP-independent efficacy, such as the myocardial fibrosis regression demonstrated in experimental rat model and patients with hypertension.

Although changes in the other vascular indices, such as the carotid IMT and FMD, were not significant in either treatment, a trend for a reduction in the carotid IMT (-3.7%, p = 0.061) was observed in the telmisartan group.

This study had several potential limitations. First, the number of participating subjects was small, and the duration of tr-
treatment may have been insufficient to demonstrate overt differences between the baseline and the end of the study and between the two groups. Because this study was designed as an open-labeled pilot study to prepare for a larger and longer prospective study, we believe the results must be interpreted with caution. Second, although we performed this study with a small number of patients, we evaluated LVMi using echocardiography. Echocardiographic quantification of ventricular mass has been perceived as less reliable because of limited echocardiography standardization and because of its reliance on left ventricular wall thickness measurements and geometric assumptions about the shape of the left ventricle.27 If we had used cardiac magnetic resonance imaging, which is regarded as the current standard of reference for an accurate and reproducible in vivo measurement of left ventricular mass, the results may have been different with this small number of patients. But, we tried to reduce potential errors with repeated LVMi measurements.

We conclude that the effects of a 12-week of treatment with two ARBs, telmisartan and valsartan, on the cardiovascular, metabolic and inflammatory parameters were not significantly different in patients with uncomplicated hypertension.

Acknowledgments

This work was supported by grants from the Korean Society of Cardiology (2006). Part of this study was presented as an abstract at the 52nd Annual Scientific Meeting of the Korean Society of Cardiology in 2008 and the ESH Congress in 2010.

REFERENCES

1) Sierra C, de la Sierra A. Angiotensin II receptor blockers: impact on ventricular mass. J Hypertens 2005; 23: 1617-23.
2) Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
3) Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009; 39: 180-4.
4) Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
5) Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 993-1003.
6) Bensou SC, Pershadisingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43: 993-1002.
7) Schupp M, Janke J, Classen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
8) Weiss D, Koos JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-54.
9) Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
10) Fiser D, Buchholz K, Haller H. Antinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-7.
11) Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
12) Hwang WM, Bae JH, Kim KY, Syng YC. Impacts of atherosclerotic coronary risk factors on atherosclerotic surrogates in patients with coronary artery disease. Korean Circ J 2005; 35: 131-9.
13) Safar ME, Smulyan H. Measurements of arterial stiffness: are they ready for clinical use? Current Cardiovascular Risk Reports 2008; 2: 268-73. doi: 10.1007/s12170-008-0050-z.
14) Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasonic assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
15) Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 430-8.
16) Kim KI, Kim Y, Kim JH, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from the Korean Epidemiology Study on Hypertension (KEY study). J Hypertens 2008; 26: 884-9.
17) Neutel JM. Choosing among renin-angiotension system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin 2010; 26: 215-22.
18) Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 117-1.
19) Lacourciere Y, Krzesinski JM, White WB, Davidsai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-10.
20) Song HG, Kim EJ, Soo HS, et al. Relative contributions of different cardiovascular risk factors to significant arterial stiffness. Int J Cardiol 2010; 139: 265-8.
21) Dihak Z, McEniry CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19: 214-9.
22) Kanellakos J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617-23.
23) Hirata K, Vlachopoulos C, Adji A, O’Rourke MF. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’ beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: 551-6.
24) Yamamoto K, Maro T, Yoshida J, et al. ACE inhibitor and angiotension II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23: 393-400.
25) Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997; 96: 4002-10.
26) Cuilla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004; 110: 552-7.
27) Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification - a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-63.